<DOC>
	<DOCNO>NCT00005954</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient brain metastasis .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity temozolomide patient brain metastasis . - Determine toxicity treatment patient . OUTLINE : Patients stratify accord type primary cancer ( lung carcinoma v breast carcinoma v malignant melanoma vs renal cell carcinoma v colorectal carcinoma v ) . Patients receive oral temozolomide daily day 1-7 15-21 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 180 patient ( 30 per stratum ) accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic lesion brain Must require immediate radiotherapy If receive prior radiotherapy , must progressive disease Evaluable disease CT scan MRI Neurologically stable PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN Alkaline phosphatase less 2 time ULN Renal : Blood urea nitrogen le 1.5 time ULN Creatinine less 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent nonmalignant systemic disease No acute infection require treatment IV antibiotic HIV negative No frequent vomit medical condition would preclude oral medication administration ( e.g. , partial bowel obstruction , inability swallow ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent hematopoietic growth factor , include epoetin alfa No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy , unless evidence disease progression No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow nonincreasing dose least 1 week prior study Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy brain , unless evidence disease progression No concurrent radiotherapy Surgery : At least 3 week since prior surgery , unless evidence disease progression , recover Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adult tumor metastatic brain</keyword>
</DOC>